Opus Genetics Reports Positive Gene Therapy Trial Data
Clinical studies show visual improvements for patients treated with OPGx-LCA5 and OPGx-BEST1 gene therapies.
Updated on Oct. 16, 2026 in Biotech
Live Poll
Should the government prioritize rapid approval for gene therapies targeting rare inherited retinal diseases?
Opus Genetics has released positive interim phase 1/2 clinical trial results for its investigational gene therapies OPGx-LCA5 and OPGx-BEST1. The data indicates significant improvements in visual acuity and retinal sensitivity among study participants.
Why it matters
The findings offer a potential treatment path for patients with Leber congenital amaurosis type 5, a condition caused by lebercilin production disruptions. These results support the progression of the company's gene therapy candidates toward further clinical evaluation.
Patients in the OPGx-LCA5 study received a subretinal dose of 1 × 10¹⁰ vector genomes per eye. The trial also utilized microperimetry to track retinal sensitivity improvements in participants.
The players
Opus Genetics
This is a gene therapy company focused on developing treatments for inherited retinal diseases.
The details
Adult patients treated with OPGx-LCA5 sustained visual acuity gains for 24 months, while pediatric participants achieved normal cone-mediated vision ranges within six months. Meanwhile, 75% of evaluable patients in the low-dose OPGx-BEST1 cohort demonstrated improved retinal sensitivity in treated areas.
Timeline
Adult patients showed visual acuity improvements sustained through 24 months.
Pediatric patients reached normal ranges for cone-mediated vision by six months.
Interim clinical data was presented at the Retina in Rio 2026 conference in October 2026.
Dosing for the OPGx-LCA5 phase 3 trial is expected in the fourth quarter of 2026.
The Tech Race
This development represents a significant advancement in the competitive landscape of AAV8-based gene therapies for degenerative retinal conditions. It positions the company as a key player in the ongoing shift toward precision genetic interventions for hereditary blindness.
These results indicate potential improvements in daily functioning, such as the ability to navigate surroundings without aids like canes. Patients and their families may monitor the upcoming phase 3 trial for further information regarding broader accessibility and clinical progress.
The takeaway
These interim results demonstrate that gene therapy may provide lasting functional vision improvements for individuals with specific genetic mutations. Patients should consult with ophthalmologists to discuss how these emerging clinical developments may align with their specific medical conditions.
What happens next
Dosing for the OPGx-LCA5 phase 3 clinical trial is scheduled to begin in the fourth quarter of 2026.
Further reading
For more information on the latest innovations in the field, visit Biotech.
Source note: This article includes information reported by BioPharm International.
Live Poll
Should the government prioritize rapid approval for gene therapies targeting rare inherited retinal diseases?
